Role of endothelin ET(A) receptors in the hypertension produced by 4- day L-nitroarginine methyl ester and cyclosporine treatment

European Journal of Pharmacology

Volumn 346, Issue 1, 1998, Pages 43-50

  Pollock, David M ^a   Polakowski, James S ^b   Opgenorth, Terry J ^b   Pollock, Jennifer S ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b ABBOTT LABORATORIES   (United States)

Author keywords

Cyclosporine; Endothelin; Endothelin ET(A) receptors; Nitric oxide (NO)

Indexed keywords

ATRASENTAN; CREATININE; CYCLOSPORIN; ENDOTHELIN A RECEPTOR; N(G) NITROARGININE METHYL ESTER; OLIVE OIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; HYPERTENSION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; URINARY EXCRETION; WEIGHT GAIN;

ANIMALS; CYCLOSPORINE; DRINKING BEHAVIOR; ENZYME INHIBITORS; FEEDING BEHAVIOR; HYPERTENSION; MALE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ENDOTHELIN A; RECEPTORS, ENDOTHELIN;

EID: 0032478576     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00043-0     Document Type: Article

References (28)

1. Abassi Z.A., Pieruzzi F., Nakhoul F., Keiser H.R. Effects of cyclosporin A on the synthesis, excretion, and metabolism of endothelin in the rat. Hypertension. 27:1996;1140-1148.
2. Akita K., Dusting G.J., Hickey H. Suppression of nitric oxide production by cyclosporine A and FK506A in rat vascular smooth muscle cells. Clin. Exp. Pharmacol. Physiol. 21:1994;231-233.
3. Amore A., Gianoglio B., Ghigo D., Peruzzi L., Porcellini M.G., Bussolino F., Costamagna C., Cacace G., Picciotto G., Mazzucco G., Sena L.M., Coppo R. A possible role for nitric oxide in modulating the functional cyclosporine toxicity by arginine. Kidney Int. 47:1995;1507-1514.
4. Bobadilla N.A., Tapia E., Franco M., Lopez P., Mendoza S., Garcia-Torres R., Alvarado J.A., Herrera-Acosta J. Role of nitric oxide in renal hemodynamic abnormalities of cyclosporine nephrotoxicity. Kidney Int. 46:1994;733-779.
5. 2 receptor antagonists on cyclosporine A renal vasoconstriction. Am. J. Physiol. 267:1994;F443-F449.
6. Davis L.S., Haleen S.K., Doherty A.M., Cody W.L., Keiser J.A. Effects of selective endothelin antagonists on the hemodynamic response to cyclosporin A. J. Am. Soc. Nephrol. 4:1994;1448-1454.
7. De Nicola L., Thomson S.C., Wead L.M., Brown M.R., Gabbai F.B. Arginine feeding modifies cyclosporine nephrotoxicity in rats. J. Clin. Invest. 92:1993;1859-1865.
8. Fast D.L., Lynch R.C., Leu R.W. Cyclosporine A inhibits nitric oxide production by L929 cells in response to tumor necrosis factor and interferon-gamma. J. Interferon Res. 13:1994;235-240.
9. Fogo A., Hellings S.E., Inagami T., Kon V. Endothelin receptor antagonism is protective in in vivo acute cyclosporine toxicity. Kidney Int. 42:1992;770-774.
10. Fujita K., Matsumura Y., Miyazaki Y., Takaoka M., Morimoto S. Role of endothelin-1 in hypertension induced by long-term inhibition of nitric oxide synthase. Eur. J. Pharmacol. 280:1995;311-316.
11. Gallego M.J., Lopez-Farre A.J., Riesco A., Monton M., Grandes S.M., Barat A., Hernando L., Casado S., Caramelo C.A. Blockade of endothelium-dependent responses in conscious rats by cyclosporine A: effect of L-arginine. Am. J. Physiol. 264:1993;H708-H714.
12. 2+. Circ. Res. 74:1994;477-484.
13. Gardner M.P., Houghton D.C., Andoh T.F., Lindsley J., Bennett W.M. Clinically relevant doses and blood levels produce experimental cyclosporine nephrotoxicity when combined with nitric oxide inhibition. Transplantation. 61:1996;1506-1512.
14. Hunley T.E., Fogo A., Iwasaki S., Kon V. Endothelin A receptor mediates functional but not structural damage in chronic cyclosporine nephrotoxicity. J. Am. Soc. Nephrol. 5:1995;1718-1723.
15. Kon V., Sugiura M., Inagami T., Harvie B.R., Ichikawa I., Hoover R.L. Role of endothelin in cyclosporine-induced glomerular dysfunction. Kidney Int. 37:1990;1487-1491.
16. Moreau P., Takase H., Küng C.F., Shawm S., Lüscher T.F. Blood pressure and vascular effects of endothelin blockade in chronic nitric oxide-deficient hypertension. Hypertension. 29:1997;763-769.
17. Nassar G.M., Badr K.F. Endothelin in kidney disease. Curr. Opin. Nephrol. Hypertens. 3:1994;86-91.
18. A-selective receptor antagonist. J. Pharmacol. Exp. Ther. 276:1996;473-481.
19. A receptor blockade prevents hypertension associated with exogenous endothelin-1 but not renal mass reduction in the rat. J. Am. Soc. Nephrol. 8:1997;1054-1060.
20. Pollock D.M., Polakowski J.S., Divish B.J., Opgenorth T.J. Angiotensin blockade reverses hypertension during long-term nitric oxide synthase inhibition. Hypertension. 21:1993;660-666.
21. Qui Q., Engles K., Baylis C. Endothelin modulates the pressor actions of acute systemic nitric oxide blockade. J. Am. Soc. Nephrol. 6:1995;1476-1481.
22. Ribeiro M.O., Antunes E., de Nucci G., Lovisolo S.M., Zatz R. Chronic inhibition of nitric oxide synthesis. A new model of arterial hypertension. Hypertension. 20:1992;298-303.
23. Richard V., Hogie M., Clozel M., Löffler B.-M., Thuillez C. In vivo evidence of an endothelin-induced vasopressor tone after inhibition of nitric oxide synthesis in rats. Circulation. 91:1995;771-775.
24. Salazar F.J., Pinilla J.M., Lopez F., Romero J.C., Quesada T. Renal effects of prolonged synthesis inhibition of endothelium-derived nitric oxide. Hypertension. 20:1992;113-117.
25. A endothelin receptor antagonism after nitric oxide synthase inhibition with L-NAME in normal rats. Circulation. 95:1997;240-244.
26. Takenaka T., Hashimoto Y., Epstein M. Diminished acetylcholine-induced vasodilation in renal microvessels of cyclosporine-treated rats. J. Am. Soc. Nephrol. 3:1992;42-50.
27. Thompson A., Valeri C.R., Lieberthal W. Endothelin receptor A blockade alters hemodynamic response to nitric oxide inhibition in rats. Am. J. Physiol. 269:1995;H743-H748.
28. A selective endothelin receptor antagonists: 1. Discovery of A-127722. J. Med. Chem. 39:1996;1039-1048.